Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma

Lachlan McDowell a,b,⇑, Georgina Casswell a, Mathias Bressel c,⇑, Karla Gough d, Allison Drosdowsky d, Andrew Coleman a, Sudi Shrestha a, Ieta D’Costa a, Tseen Fua a, Albert Tiong a, Chen Liu a, Sweet Ping Ng a, Benjamin Solomon b,e, Danny Rischin b,e

a Department of Radiation Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia
b Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia
c Centre of Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia
d Department of Cancer Experiences, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia
e Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria, Australia

Abstract

Purpose: The purpose of this study was to compare self-reported health-related quality of life (QoL) and symptom burden in early stage tonsillar carcinoma patients treated with unilateral (URT) and bilateral radiotherapy (BRT).

Methods and materials: This is a secondary analysis of a larger study assessing patient reported outcomes in human papillomavirus (HPV) oropharyngeal cancer (OPC) patients. Recruited patients were enrolled from November 2018 to May 2019. Of the 136 patients recruited to the main study, 43 were eligible for this substudy (22 URT, 21 BRT), with a median age and follow up of 58.2 and 3.0 years respectively. The two groups were balanced with respect to patient, tumor and treatment factors with the exception of higher rates of T2 disease (27% v 71%, p = 0.006) and more extensive GTV nodal volumes (11.0 v 25.5cc, p = 0.006) in the BRT group.

BRT patients had lower global health status/QoL (84 v 69, p = 0.0005) and social functioning scores (93 vs 78, p = 0.033) on the EORTC QLQ-C30, and higher symptom severity (0.6 vs. 2.0, p = 0.001) and symptom interference scores (0.8 vs. 2.0, p = 0.010) on the MDASI-HN. Four of the six largest differences observed on MDASI-HN items were attributable to radiotherapy technique (dry mouth, mucous, difficulty swallowing/chewing and taste), with corresponding dose differences to the respective organs (contralateral parotid, oral cavity and pharyngeal constrictors). In every instance, severity of symptoms was worse on average for patients treated with BRT.

Conclusions: In the highly conformal radiotherapy era, BRT in early HPV tonsillar cancer survivors has an enduring impact on long-term QoL and toxicity.

1. Introduction

There is controversy regarding the appropriateness of unilateral radiotherapy (URT) in lateralized tonsillar tumors. ASTRO clinical practice guidelines [1] recommend URT in well-lateralized T1-T2 tonsillar tumors with N0-N1 disease (AJCC 7th edition [2]). In cases of N2a, shared-decision making was recommended, with consideration to the benefits of URT against the risk of contralateral nodal failure (CNF) and salvage therapy. However, in contemporary prac-
tice the actual benefit of URT is largely unknown, having not been quantified using patient-reported outcome measures (PROMs), which include both quality of life (QoL) and toxicity measures. Thus the shared decision making relies largely on the treating clinician communicating their anecdotal experience to the patient.

The opposing argument for BRT is to reduce the risk of CNF. In the setting of a well-lateralized tonsillar tumour, low rates of CNF have been reported with URT where there are multiple ipsilateral neck nodes [3–14]. Following URT, these series also suggest that salvage is largely successful where CNF is isolated. While clinical trials continue to explore the optimal de-intensification strategy with various combinations of systemic, surgical and radiation treatments, increased utilization of URT may provide an alternative and effective strategy for selected patients.

The aim of this study was to provide an estimate of the long-term difference between URT and BRT based on patient-reported outcome measures (PROMs). We report the differences in an exclusive population of patients with human papillomavirus (HPV) associated, early stage tonsillar cancers treated with highly conformal radiotherapy.

2. Methods and materials

2.1. Participants

From November 2018 to May 2019 eligible patients were prospectively recruited to a larger study reporting QoL and exploring unmet needs in HPV-OPC survivors. The eligibility criteria for this secondary analysis were: (1) aged ≥18; (2) histologically confirmed HPV+ (determined by p16 status) lateralized tonsil carcinoma (limited to extension to the ipsilateral palate); (3) AJCC 7th edition T1-T2, N1-N2b disease [2]; (4) treated with curative intent intensity modulated radiotherapy (IMRT) ± chemotherapy; (5) English speaking; and (6) ≥12 months following treatment completion. Patients were excluded if they had base of tongue involvement, recurrent disease, another active malignancy or were enrolled on another study. The study was approved by our institutional ethics board (LNR/46990/PMCC-2018).

2.2. Demographic, disease and treatment variables

Patient demographic, disease and treatment variables were collected from patient medical records.

2.3. Patient reported outcome measures

Multiple patient-reported outcome measures (PROMs) were collected for the larger study. This study included the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and the MD Anderson Symptom Inventory for head and neck cancer (MDASI-HN).

The EORTC QLQ-C30 is a 30-item inventory which maps to a global health status/QoL score, five functional scales, three symptom scales and six single-item scales [15]. Only the global health status/QoL and functional scales are reported in this study. Higher scores indicate better quality of life and functioning, respectively. Published guidelines were used to support the interpretation of differences in the QLQ-C30 domains [16].

The MDASI-HN assesses cancer symptoms (22 items) and their interference on daily activities (six items) [17]. The symptom items include 13 general and nine head and neck cancer symptoms. The mean symptom severity score is the average of the 22 symptom items and the mean symptom interference score is the average of the six interference items. The minimally important difference (MID) is estimated at 0.98–1.21 [17].

2.4. Statistical analysis

Descriptive statistics of baseline characteristics were reported and compared by treatment laterality using t-test, Fisher exact test and Wilcoxon rank sum test, as appropriate. Tobit regression was used to compare PROMs by laterality. This analysis was considered exploratory and no multiplicity adjustment was performed. All statistical analyses were performed in R version 3.6.0 (2015).

3. Results

In total, 136 patients were recruited to the main study. Forty-three (22 URT, 21 BRT) met the eligibility criteria for this substudy. Demographic, disease and treatment details are presented in Table 1. Of the patients receiving bilateral treatment in this study, all patients had disease limited to the ipsilateral hemi-palate, however the decision to treat bilateral was based on the extent of nodal disease in 11/21 (52%) and on soft palate invasion in 10/21 (48%).

The EORTC QLQ-C30 and MDASI-HN scores are presented in Tables 2 and 3. MDASI-HN severity ratings are presented in Table 4. In every instance scores were numerically favoured patients treated with URT.

The estimated clinical impact of the differences were considered medium for the global health status/QoL, cognitive and social functioning domains and trivial for the physical and role functioning domains.

MDASI-HN items were ranked in order of the magnitude of the difference between the URT and BRT groups (Table 3). Four of the six largest differences observed were attributable to radiotherapy technique: dry mouth, mucous, difficulty swallowing/chewing and taste. Correspondingly, dosimetric differences to the contralateral parotid, oral cavity and pharyngeal constrictors were significantly different between the URT and BRT cohorts (Table 1).

4. Discussion

To our knowledge this is one of the few studies to contrast self-reported, long-term QoL in early-stage tonsillar carcinoma patients treated with definitive URT and BRT in the IMRT era, suggesting worse long-term QoL and toxicity with BRT. In contrast to other series reporting toxicity outcomes [18–20], all our patients were confirmed cases of HPV + tonsillar carcinoma and all were treated with IMRT. This is a cross-sectional study, and while we accept some inevitable selection bias, this data illustrates the relative estimate of the long-term impact of BRT in patients with lateralized tonsillar carcinoma.

We noted medium-sized differences in global health status/QoL (84 v 69, p = 0.0005), social functioning (93 vs 78, p = 0.033) and cognitive function (86 v 75, p = 0.129), in favour of URT [16]. The differences in physical and role functioning were considered trivial. Differences in the MDASI-HN mean severity (0.6 vs 2.0, p = 0.001) and mean interference scores (0.8 vs 2.0, p = 0.010) were beyond the reported MID [17]. While patients treated with URT infrequently reported their symptoms as severe (≥7 on the MDASI-HN), this was numerically more frequent in the bilateral group, especially in the items considered most likely to be impacted by BRT (Table 4). When ranking the MDASI-HN items according to the largest difference in mean scores between the URT and BRT groups, four of the six items with the largest difference were primarily attributable to differences in radiotherapy technique, including dry mouth, problems with mucous, difficulty swallowing or chewing and taste. Although we did not have baseline PROM data to assess longitudinal changes, in the HPV-era, patients with small tonsillar tumors generally present with asymptomatic lymphadenopathy with relatively good QoL at baseline.
Gunn et al. have reported long-term MDASI-HN outcomes in survivors of early stage tonsillar fossa cancers, (T1-2, N0-N2b) treated with IMRT [18]. In contrast to our findings, the only significant differences between URT and BRT (in patients treated with RT alone) was the mean score of the skin-related item and higher rates of moderate to severe dry mouth (40% v 25%, \( p = 0.03 \)). The reason for the discordance to our findings is not obvious. While our series included patients treated mostly with concurrent chemoradiotherapy (86%), the Gunn et al. series compared only patients treated with RT alone (62%) in the URT/BRT analysis. Another contributing factor may be differences by HPV/p16 status, an independent factor for QoL outcomes [21]. While our study exclusively recruited patients with HPV+/p16 + disease, the status in the majority of cases (78/139; 56%) in their series was unknown, although it was positive in the majority where the status was known (57/61). We also noted that the assessment time was longer in their cohort (mean 5.1 versus 3.2 years), although in general it would be expected that for most, the toxicity profile would remain stable over this interval. A small series (n = 30; 15 URT, 15 BRT) from Roswell Park has also been presented in abstract form, reporting sim-

Table 1
Demographic, disease and treatment characteristics.

| Variable                        | Total (n = 43) | Unilateral (n = 22) | Bilateral (n = 21) | p-value |
|---------------------------------|---------------|---------------------|--------------------|---------|
| Mean Age (years, range)         | 58.2 [46.2–70.4] | 59.1 [46.2–70.4] | 57.3 [46.9–68.3] | 0.232*  |
| Partnered Relationship          | 16 (73%)      | 16 (76%)            |                    | 1.000   |
| Current Smoker                  | 8 (18%)       | 3 (14%)             | 5 (24%)            | 0.457   |
| Current Alcohol consumer        | 32 (74%)      | 18 (82%)            | 15 (71%)           | 0.488   |
| Charlson Co-morbidity Score (range) | 1.74 [0–6] | 1.77 [0–5]          | 1.71 [0–6]         | 0.890   |
| Mean Follow-up (years, SD)      | 3.2 (1.2)     | 3.3 (1.2)           | 3.1 (1.2)          | 0.445*  |
| T stage                         |               |                     |                    |         |
| T1                              | 22 (51%)      | 16 (73%)            | 6 (29%)            |         |
| T2                              | 21 (49%)      | 6 (27%)             | 15 (71%)           |         |
| N stage                         |               |                     |                    |         |
| N1                              | 10 (23%)      | 5 (23%)             | 5 (24%)            | 0.714†  |
| N2a                             | 4 (9%)        | 3 (14%)             | 1 (5%)             |         |
| N2b                             | 29 (67%)      | 14 (64%)            | 15 (71%)           |         |
| No. of nodes                    |               |                     |                    | 0.132†  |
| 1                               | 14 (33%)      | 8 (36%)             | 6 (29%)            |         |
| 2                               | 18 (42%)      | 11 (50%)            | 7 (33%)            |         |
| 3                               | 6 (14%)       | 3 (14%)             | 3 (14%)            |         |
| 4                               | 1 (2%)        | 0 (0%)              | 1 (5%)             |         |
| 5                               | 2 (5%)        | 0 (0%)              | 2 (10%)            |         |
| 7                               | 1 (2%)        | 0 (0%)              | 1 (5%)             |         |
| 9                               | 1 (2%)        | 0 (0%)              | 1 (5%)             |         |
| Median Nodal GTV Volume (cc, median, range) | 13.4 [3.1–71.4] | 11.0 [3.1–36.5] | 25.5 [6.2–71.4] | 0.006*  |
| Radiotherapy Dose (Gy)          |               |                     |                    |         |
| 66                              | 3 (7%)        | 3 (14%)             | 0 (0%)             | 0.167†  |
| 68                              | 1 (2%)        | 1 (5%)              | 0 (0%)             |         |
| 70                              | 39 (91%)      | 18 (82%)            | 21 (100%)          |         |
| Chemotherapy                    |               |                     |                    |         |
| No                              | 6 (14%)       | 5 (24%)             | 1 (5%)             | 0.184†  |
| Yes                             | 36 (86%)      | 16 (76%)            | 20 (95%)           |         |
| Mean Oral Cavity dose (Gy, SD)  | 35.3 (7.6)    | 30.2 (5.5)          | 40.9 (5.3)         | <0.001* |
| Mean Pharyngeal constrictor dose (Gy, SD) | 44.2 (6.5) | 39.6 (5.0)          | 49.3 (3.3)         | <0.001* |
| Mean Ipsilateral parotid dose (Gy, SD) | 42.4 (10.3) | 39.7 (9.8)          | 45.4 (10.3)        | 0.089†  |
| Mean Contralateral parotid dose (Gy, SD) | 17.6 (8.2) | 10.3 (3.2)          | 25.8 (1.0)         | <0.001* |

GTV – Gross tumor volume, SD = standard deviation, *t-test; †Fisher exact test; ‡Wilcoxon rank sum test.

Table 2
EORTC Global health status and functional domains and MDASI-HN summary scores.

| Measure                                | Radiotherapy Technique | Estimate difference (95% CI)* | Clinical Impact of Difference [16] | p-value |
|----------------------------------------|------------------------|-------------------------------|------------------------------------|---------|
|                                        | Unilateral (n = 22) Mean (SD) | Bilateral (n = 21) Mean (SD) |                                    |         |
| EORTC QLQ-C30 domains                  |                        |                               |                                    |         |
| Global health status                   | 84 (17)                | 69 (21)                       | 16.4 (5.1, 27.7)                   | Medium  | 0.005  |
| Physical functioning                   | 92 (12)                | 89 (15)                       | 4.5 (–3.0, 11.9)                   | trivial | 0.246  |
| Role functioning                       | 90 (25)                | 88 (21)                       | 4.9 (–8.1, 18.0)                   | trivial | 0.467  |
| Emotional functioning                  | 84 (19)                | 77 (19)                       | 8.9 (–2.8, 20.5)                   | –       | 0.139  |
| Cognitive functioning                  | 86 (18)                | 75 (29)                       | 11.2 (–3.2, 25.7)                  | medium  | 0.129  |
| Social functioning                     | 93 (13)                | 78 (30)                       | 16.0 (10.0, 30.0)                  | medium  | 0.033  |
| MDASI-HN Summary Scores                |                        |                               |                                    |         |
| Module Symptom Severity                | 0.6 (0.6)              | 2.0 (1.9)                     | –1.3 (–2.0, –0.5)                  | –       | 0.001  |
| Symptom Interference                   | 0.8 (1.5)              | 2.0 (2.1)                     | –1.4 (–2.4, –0.4)                  | –       | 0.010  |

*Marginal effect estimate from Tobit model; †emotional domain was omitted from the analysis by Cocks et al. [16].

Gunn et al. have reported long-term MDASI-HN outcomes in survivors of early stage tonsillar fossa cancers, (T1-2, N0-N2b) treated with IMRT [18]. In contrast to our findings, the only significant differences between URT and BRT (in patients treated with RT alone) was the mean score of the skin-related item and higher rates of moderate to severe dry mouth (40% v 25%, \( p = 0.03 \)). The reason for the discordance to our findings is not obvious. While our series included patients treated mostly with concurrent chemoradiotherapy (86%), the Gunn et al. series compared only patients treated with RT alone (62%) in the URT/BRT analysis. Another contributing
### Table 3
MDASI-HN items ranked by difference between unilateral and bilateral treatment.

| MDASI-HN item                    | Technique                  | Mean Symptom items | Numerical Difference (bilateral – unilateral) |
|----------------------------------|----------------------------|--------------------|-----------------------------------------------|
|                                  | Unilateral (n = 22)        | Bilateral (n = 21) |                                               |
|                                  | Mean (SD)                  | Mean (SD)          |                                               |
| Mean Symptom items               |                            |                    |                                               |
| Dry mouth                        | 3.0 (3.1)                  | 5.4 (3.6)          | 2.4                                           |
| Difficulty swallowing/chewing   | 1.2 (1.8)                  | 3.5 (3.4)          | 2.3                                           |
| Fatigue                          | 2.2 (2.5)                  | 4.5 (2.8)          | 2.3                                           |
| Mucus in your mouth and throat   | 0.8 (1.7)                  | 3.0 (3.5)          | 2.2                                           |
| Sleep                            | 2.0 (2.5)                  | 4.1 (3.1)          | 2.1                                           |
| Taste                            | 1.1 (1.6)                  | 3.0 (3.9)          | 1.9                                           |
| Drowsy                           | 1.6 (2.3)                  | 3.3 (3.0)          | 1.7                                           |
| Appetite                         | 1.0 (2.0)                  | 2.6 (3.5)          | 1.6                                           |
| Mouth/throat sores               | 0.1 (0.4)                  | 1.7 (2.8)          | 1.6                                           |
| Teeth or Gums                    | 0.9 (1.7)                  | 2.4 (3.4)          | 1.5                                           |
| Pain                             | 0.5 (1.4)                  | 2.0 (2.6)          | 1.5                                           |
| Shortness of breath              | 0.7 (1.5)                  | 2.2 (2.9)          | 1.5                                           |
| Remembering things               | 1.8 (2.2)                  | 3.2 (3.3)          | 1.4                                           |
| Voice/speech                     | 0.2 (0.5)                  | 1.2 (1.6)          | 1.0                                           |
| skin pain/burning/rash           | 0.2 (0.9)                  | 1.1 (2.7)          | 0.9                                           |
| Choking/coughing                 | 0.2 (0.4)                  | 1.1 (1.7)          | 0.9                                           |
| Distress                         | 1.5 (2.7)                  | 2.4 (3.0)          | 0.9                                           |
| Numbness or tingling             | 0.8 (1.8)                  | 1.6 (2.2)          | 0.8                                           |
| Sad                              | 1.2 (2.0)                  | 2.0 (2.6)          | 0.8                                           |
| Constipation                     | 0.7 (1.9)                  | 1.3 (2.7)          | 0.6                                           |
| Nausea                           | 0.2 (1.1)                  | 0.6 (1.9)          | 0.4                                           |
| Vomiting                         | 0.1 (0.4)                  | 0.5 (1.5)          | 0.4                                           |
| Interference items               |                            |                    |                                               |
| Relations with other people      | 0.8 (1.7)                  | 2.6 (2.9)          | 1.8                                           |
| Enjoyment of Life                | 0.9 (1.9)                  | 2.3 (2.6)          | 1.4                                           |
| General activity                 | 0.6 (1.6)                  | 1.8 (2.3)          | 1.2                                           |
| Mood                             | 0.9 (1.7)                  | 2.0 (2.3)          | 1.1                                           |
| Work                             | 1.0 (1.8)                  | 2.1 (2.6)          | 1.1                                           |
| Walking                          | 0.7 (1.6)                  | 1.3 (2.3)          | 0.6                                           |

*1 patient did not answer from unilateral group; 1 patient did not answer from bilateral group; 2 patients did not answer from bilateral group.

### Table 4
MDASI-HN symptom severity ratings.

| MDASI-HN Item       | Unilateral (n = 22) | Bilateral (n = 21) |
|---------------------|---------------------|--------------------|
|                     | None-mild (0–4)     | Moderate (5–6)     | Severe (7–10) |
|                     | None-mild (0–4)     | Moderate (5–6)     | Severe (7–10) |
| Symptom items       |                     |                    |                |
| Dry mouth           | 15 (68%)            | 3 (14%)            | 4 (18%)        |
| swelling/chewing   | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Fatigue             | 16 (73%)            | 5 (23%)            | 1 (5%)         |
| Mucus mouth/throat  | 21 (95%)            | 0 (0%)             | 1 (5%)         |
| Sleep               | 18 (82%)            | 1 (5%)             | 3 (14%)        |
| Taste               | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Drowsy              | 18 (82%)            | 3 (14%)            | 1 (5%)         |
| Appetite            | 19 (86%)            | 3 (14%)            | 1 (5%)         |
| Mouth/throat sores  | 21 (100%)           | 0 (0%)             | 0 (0%)         |
| Teeth or Gums       | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Pain                | 21 (95%)            | 1 (5%)             | 0 (0%)         |
| Shortness of breath | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Remembering things  | 19 (86%)            | 3 (14%)            | 1 (5%)         |
| Voice/speech        | 22 (100%)           | 0 (0%)             | 0 (0%)         |
| skin pain/burning/rash | 22 (100%)           | 0 (0%)             | 0 (0%)         |
| Choking/coughing    | 22 (100%)           | 0 (0%)             | 0 (0%)         |
| Distress            | 19 (86%)            | 0 (0%)             | 3 (14%)        |
| Numbness or tingling| 21 (95%)            | 0 (0%)             | 1 (5%)         |
| Sad                 | 19 (86%)            | 3 (14%)            | 0 (0%)         |
| Constipation        | 21 (95%)            | 0 (0%)             | 1 (5%)         |
| Nausea              | 21 (95%)            | 1 (5%)             | 0 (0%)         |
| Vomiting            | 22 (100%)           | 0 (0%)             | 0 (0%)         |
| Interference items  |                     |                    |                |
| Relations with other people | 20 (91%)           | 2 (9%)             | 0 (0%)         |
| Enjoyment of Life   | 19 (86%)            | 3 (14%)            | 1 (5%)         |
| General activity    | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Mood                | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Work                | 20 (91%)            | 2 (9%)             | 0 (0%)         |
| Walking             | 20 (91%)            | 2 (9%)             | 0 (0%)         |

*1 patient did not answer from unilateral group; 1 patient did not answer from bilateral group; 2 patients did not answer from bilateral group.
Reported contralateral outcomes in well-lateralized tonsillar tumors treated with unilateral radiation limited to results in patients with multiple ipsilateral neck nodes (N2b). Use of chemotherapy were not included in the abstract [20]. Improved toxicity profile (EORTC QLQ-C30 and H&N35 modules), similar findings to ours, in that URT may be associated with an isolated CNF (Table 5). A comprehensive study of clinician-scored toxicity by Jensen et al. with field based radiotherapy treatment showed a more favourable toxicity profile with URT over BRT [19]. Lower mean scores and rates of moderate to severe toxicity were seen with respect to xerostomia, dysphagia, hoarseness, atrophy, fibrosis and oedema. However, patients were treated with opposed laterals in the BRT group and a wedge pair in the URT cases. While this data is not necessarily applicable in the highly conformal radiotherapy era, our series consisting exclusively of IMRT-treated patients demonstrated similar findings.

The available literature suggests a low CNF rate with URT in N2b disease (approximating 5%) and a lower unsalvageable rate of patients who truly experience an isolated CNF (Table 5). A contemporary systematic review of URT outcomes reported a CNF rate of 1.47% (9/325), 4.15% (11/265) and 4.84% (9/186) in N0, N1 and N2b disease, respectively [22]. While these series reported “N2b” outcomes, it is possible that the majority of included cases consisted of reasonably low volume N2b disease. In series where URT is delivered following surgical management of the lateralized tonsil, similar findings have been demonstrated [11,23]. While the rationale to pursue BRT may reduce the risk of CNF in some, it will not safeguard against locoregional failure in all cases, even where maximal intensity therapy is undertaken. An important consideration in the decision-making process is also the increasing risk of distant metastases with an increasing burden of nodal disease in the ipsilateral neck and in the presence of either radiological extracapsular extension or a matted nodal mass [24–26]; risks that may be in excess of the CNF rate.

Our study has several limitations including its small sample size, non-randomised groups and selection bias, absence of pretreatment PROM assessment and heterogeneity in PROM time-point assessment. This led to some imbalance between the groups, evidenced in differences by T-stage and GTV nodal volume between the URT and BRT groups. There was an approximate even distribution of patients receiving bilateral treatment on the basis of nodal disease and soft palate invasion, although all had disease limited to the ipsilateral hema palate. However, this report is not designed to determine the efficacy of treatment, rather to provide an estimate of the potential toxicity of contralateral treatment; we would suggest that the impact of extending prophylactic coverage across the midline is likely to have more of an impact on toxicity than slightly larger volumes of primary tumour coverage. There were other factors, such as the prescribed dose and chemotherapy utilisation which were not statistically different between the two groups, but numerically favoured the URT group. We did also not find any differences in social (partner status; alcohol and smoking status) and medical factors (medical comorbidity). However, even with these limitations, this data adds to the limited body of literature in estimating the patient perspective in the URT vs BRT debate, and appears to be consistent with the clinical experience in long-term outcomes of patients treated with URT and BRT.

In summary, our study estimates the potential impact of BRT on QoL and toxicity in patients with early stage tonsillar tumours. This should be factored into clinical decision making and provides impetus for prospectively evaluating the efficacy of URT as method of treatment de-intensification in patients with lateralised tonsillar tumors with more extensive nodal disease.

5. Conclusions

In the highly conformal radiotherapy era, the decision to treat the contralateral neck may impact patients’ long-term QoL and toxicity. In the setting of low CNF rates and high salvageability, prospective evaluation of unilateral RT in more advanced ipsilateral neck disease is warranted.

6. Funding statement

None.
Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO evidence-based clinical practice guideline. Pract Radiat Oncol. 2017;7:246–53.
[2] Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
[3] Lynch J, Lal P, Schick U, Nutting CM, Newbold K, Harrington K, et al. Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. Oral Oncol. 2014;50:901–6.
[4] Al-Mamgani A, van Rooij P, Fransen D, Levendag P. Unilateral neck irradiation for well-lateralized oropharyngeal cancer. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2013;106:69–73.
[5] Dan TD, Raben D, Schneider CJ, Hockstein NG, Witt RL, Dzeda M, et al. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach. Oral Oncol 2015;51:616–21.
[6] Maskell D, Buckley H, Sisson K, Roques T, Gospontas K. Ipsilateral neck radiotherapy in N2b well-lateralized tonsil cancer - approach with caution. Head Neck. 2019.
[7] Kennedy WR, Herman MP, Deranyagala RL, Am enduring R, Werning JW, Dziegielewski PT, et al. Ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. Eur Arch Oto-Rhino-Laryngol: Off J Eur Feder Oto-Rhino-Laryngol Soc 2016;273:2151–6.
[8] Chronowski GM, Garden AS, Morrison WH, Frank SJ, Schwartz DL, Shah SJ, et al. Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys 2012;83:204–9.
[9] Hu KS, Mourad WF, Gamez M, Saldieh J, Lin W, Jacobson AS, et al. Low rates of contralateral neck failure in unilaterally treated oropharyngeal squamous cell carcinoma with prospectively defined criteria of lateralization. Head Neck. 2017;39:1647–54.
[10] Gottumukkala S, Pham NL, Sumer B, Myers L, Truelson J, Nedzi L, et al. Risk of contralateral nodal failure following ipsilateral IMRT for node-positive tonsillar cancer. Oral Oncol 2017;75:35–8.
[11] Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: results of a prospective management approach. Int J Radiat Oncol Biol Phys 2009;74:1365–70.
[12] Koo TR, Wu HG. Long-term results of ipsilateral radiotherapy for tonsil cancer. Radiat Oncol J 2013;31:66–71.
[13] Huang SH, Waldron J, Bratman SV, Su J, Kim J, Bayley A, et al. Re-evaluation of Ipsilateral Radiation for T1–T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. Int J Radiat Oncol Biol Phys 2017;98:159–69.
[14] Liu C, Dutta G, Peters Lj, Rischin D, Co rry J. Tonsillar cancer: the Peter MacCallum experience with unilateral and bilateral irradiation. Head Neck 2014;36:317–22.
[15] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
[16] Cocks K, King MT, Velikova G, Martyn St James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol 2011;29:89–96.
[17] Clee land CS. The M.D. Anderson Symptom Inventory User Guide. 2010. Version 1 ed2010.
[18] Gun nb GB, Hansen CC, Garden AS, Fuller CD, Mohamed AS, Morrison WH, et al. Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: results from a symptom assessment study. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2015;117:132–8.
[19] Jensen K, Overgaard M, Grau C. Morbidity after ipsilateral radiotherapy for oropharyngeal cancer. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2007;85:90–7.
[20] Platek A, Platek ME, Jovoli AJ, De Graaff LH, Wooten KE, Hassan A, et al. Patients report less severe symptoms with unilateral radiation therapy than bilateral radiation therapy for tonsillar squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2018;100:1404.
[21] Ringash J, Fisher R, Peters L, Tro tti A, O’Sullivan B, Corry J, et al. Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: a substudy of randomized trial trans-tasman radiation oncology group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys 2017;97:678–86.
[22] Al-Mamgani A, van Werkhoven E, Navran A, Karakkulucku B, Hamming-Vrieze O, Machiels M, et al. Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: a literature-based critical review. Cancer Treat Rev 2017;55:102–8.
[23] Chin RI, Rao VJ, Hwang MY, Spencer CR, Pierro M, De Wees T, et al. Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palate tonsil. Cancer 2017;123:4594–607.
[24] Vainshtein JM, Spector ME, Ibrahim M, Bradford CR, Wolf GT, Stennmark MH, et al. Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. Head Neck 2016;38(Suppl 1):E805–14.
[25] Spector ME, Chinn SB, Bellile E, Gallagher KK, Ibrahim M, Vainshtein J, et al. Matted nodes as a predictor of distant metastasis in advanced-stage III/IV oropharyngeal squamous cell carcinoma. Head Neck 2016;38:184–90.
[26] Bill-falk-Kelly A, Yu E, Su J, O’Sullivan B, Waldron J, Ringash J, et al. Radiologic extranodal extension portends worse outcome in C+ TNM-8 stage I human papillomavirus-mediated oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2019;104:1017–27.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
McDowell, L; Casswell, G; Bressel, M; Gough, K; Drosdowsky, A; Coleman, A; Shrestha, S; D'Costa, I; Fua, T; Tiong, A; Liu, C; Ng, SP; Solomon, B; Rischin, D

Title:
Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma

Date:
2020-03-01

Citation:
McDowell, L., Casswell, G., Bressel, M., Gough, K., Drosdowsky, A., Coleman, A., Shrestha, S., D'Costa, I., Fua, T., Tiong, A., Liu, C., Ng, S. P., Solomon, B. & Rischin, D. (2020). Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma. CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 21, pp.85-90. https://doi.org/10.1016/j.ctro.2020.01.004.

Persistent Link:
http://hdl.handle.net/11343/245609

File Description:
published version

License:
CC BY-NC-ND